Pacira Pharmaceuticals Inc. Sets New 1-Year High at $69.74 (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) set a new 52-week high during trading on Friday, Analyst Ratings News reports. The stock traded as high as $69.74 and last traded at $68.94, with a volume of 411,510 shares. The stock had previously closed at $66.25.
A number of research firms have recently commented on PCRX. Analysts at Wedbush reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note to investors on Monday, November 4th. They now have a $59.00 price target on the stock. Analysts at Jefferies Group raised their price target on shares of Pacira Pharmaceuticals from $58.00 to $60.00 in a research note to investors on Monday, November 4th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $55.20.
Pacira Pharmaceuticals has a 52-week low of $18.98 and a 52-week high of $69.39. The stock’s 50-day moving average is $58. and its 200-day moving average is $48.03. The company’s market cap is $2.298 billion.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.